Trial Profile
Phase I/II Study With Bendamustine and Temsirolimus in Patients With Relapsed or Refractory Mantle Cell Non-hodgkin's Lymphoma (NHL) Not Eligible for High Dose Chemotherapy and Autologous/Allogeneic Stem Cell Transplantation
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase I/II
Latest Information Update: 09 Feb 2022
Price :
$35
*
At a glance
- Drugs Bendamustine (Primary) ; Temsirolimus (Primary)
- Indications Mantle-cell lymphoma
- Focus Adverse reactions; Therapeutic Use
- 09 Feb 2022 This trial has been discontinued (End Date: 17 Mar 2011), according to European Clinical Trials Database record.
- 01 Jun 2013 New source identified and integrated (European Clinical Trials Database, EudraCT2009-014844-13).
- 15 Mar 2011 Status changed from recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov.